Abstract
Target populations for chemoprevention trials should include those at higher than average risk for the development of prostate cancer as defined by explicit epidemiologic and genetic criteria. Such populations include a “primary prevention” group without histologic or clinical evidence of cancer, and several clinical models of “secondary prevention,” including those with clinically evident disease prior to definitive therapy and those at high risk of recurrence after therapy based on histology and/or biochemical status. Each risk group and clinical model has potential advantages and disadvantages, and the mechanisms which underlie disease development and progression in each group may be unique. These observations give rise to many potential clinical trials of specific agents. These trials should also include collection of data on potentially confounding influences on disease development and progression. Preclinical, epidemiologic, and Phase II data suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. The experience of the Prostate Cancer Prevention Trial (PCPT) demonstrates the interest and dedication of healthy men to long-term studies of cancer prevention. SELECT, the Selenium and Vitamin E Cancer Prevention Trial, is an intergroup phase III, randomized, double-blind, placebo-controlled, population-based clinical trial designed to test the efficacy of selenium and vitamin E alone and in combination in the prevention of prostate cancer which builds on secondary analyses of large-scale chemoprevention trials for other cancers and the lessons of PCPT.
Keywords
- Prostate Cancer
- Prostate Specific Antigen
- Clinical Model
- Prostatic Intraepithelial Neoplasia
- Serum Prostate Specific Antigen
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Zlotta AR, Schulman CC (1999) Chemoprevention of prostate cancer. Rev Urol 1:35–40
Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics CA Cancer J Clin 49:831
Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Issacs S, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, et al (1995) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274:1371–1374
Carter BS, Bova GS, Beaty T (1993) Hereditary prostate cancer: epidemiologic and clinical features. J UroI 150:797–802
Zlotta AR, Schulman CC (1999) Clinical evolution of prostatic intraepithelial neoplasia. Eur Urol 35:498–503
Eeles RA, Durocher F, Edwards S, Teare D (1998) Linkage analysis of chromosome 1q markers in 136 prostate cancer families. Am J Human Genet 62:653–658
Jhaveri FM, Zippe CD, Klein EA, Kupelian PA (1999) Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10 year results. Urology 54:884–890
Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541–1548
Paris PL, Kupelian PA, Hall J, Levin HS, Klein EA, Casey G, Witte JS (1999) Association of a CYP3A4genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 10:901–990
Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JK (1999) Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354:975–978
Platz EA, Kantoff PW, Giovannucci E (2000) Epidemiology and risk factors for prostate cancer. In: Klein EA (ed) Management of prostate cancer. Humana Press, Totowa, NJ, pp 19–46
Heinonen OP, Albanes D, Huttunen JK, et al (1998) Prostate cancer and supplementation with α-tocopherol and β-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440–446
Clark LC, Combs GF Jr, Turnbull BW, et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276:1957–1963
National Academy of Sciences (1989) Recommended dietary allowances, 10th edn. National Academy Press, Washington, pp 217–24
Combs GF Jr. Clark LC (1997) Selenium and cancer. In: Garewal H (ed) Antioxidants and disease prevention. CRC Press, New York
Yoshizawa K, Willett WC, Morris SJ, et al (1998) Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 90:1219–1224
Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY, Yu Y, Liu BQ, Tangrea J, Sun YH, Liu F, Fraumeni JF Jr. Zhang YH, Li B (1993) Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85:1483–1492
Li JY, Taylor PR, Li B, Dawsey S, Wang GQ, Ershow AG, Guo W, Liu SF, Yang CS, Shen Q, Wang W, Mark SD, Zou XN, Greenwald P, Wu YP, Blot WJ (1993) Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 85:1492–1498
Clark LC, Dalkin B, Krongrad A, et al (1998) Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 81:730–734
Burton GW, Ingold KU (1981) Autoxidation of biological molecules. 1. The antioxidant activity of vitamin E and related chain-breaking phenolic antioxidants in vitro. J Am Chern Soc 103:6472
Machlin LJ (1991) Vitamin E. In LJ Machlin (ed) Handbook of vitamins, 2nd edn. Marcel Dekker, New York
Pappas AM (1998) Vitamin E: tocopherols and tocotrienols. In: Pappas AM (ed) Antioxidant status, diet, nutrition, and health. CRC, Boca Raton, pp 150–155
Azzi A, Boscoboinik D, Marilley D, Ozer NK, Stauble B, Tasinato A (1995) Vitamin E: a sensor and an information transducer of the cell oxidation state. Am J Clin Nutr 62:1337s–1346s
Mahoney CW, Azzi A (1988) Vitamin E inhibits protein kinase C activity. Biochem Biophys Res Commun 154:694–697
Chatelain E, Boscoboinik DO, Bartoli GM, et al (1993) Inhibition of smooth muscle cell proliferation and protein kinase C activity by tocopherols and tocotrienols. Biochim Biophys Acta 1176:83–89
Ottino P, Duncan JR (1997) Effect of alpha-tocopherol succinate on free radical and lipid peroxidation levels in BL6 melanoma cells. Free Radic Bioi Med 22:1145–1151
Mahoney CW, Azzi A (1988) Vitamin E inhibits protein kinase C activity. Biochem Biophys Res Commun 154:694–697
Wang W, Higuchi CM (1995) Induction ofNAD(P)H:quinone reductase by vitamins A, E and C in Colo205 colon cancer cells. Cancer Lett 98:63–69
Traber MG, Packer L (1995) Vitamin E: beyond antioxidant function. Am J Clin Nutr 62:1501–1504
Israel K, Sanders BG, Kline K (1995) RRR-alpha-tocopheryl succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. Nutr Cancer 24:161–169
Kishimoto M, Yano Y, Yajima S, Otani S, Ichikawa T, Yano T (1998) The inhibitory effect of vitamin E on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in mice based on the regulation of polyamine metabolism. Cancer Lett 24:173–178
Sigounas G, Anagnostou A, Steiner M (1997) dl-alpha-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. Nutr Cancer 28:30–35
Umeda F, Kato K-I, Muta K, Ibayashi H (1982) Effect of vitamin E on function of pituitary-gonadal axis in male rats and human studies. Endocrinol Jpn 29:287–292
USDA (U.S. Department of Agriculture) (1987) Nationwide food consumption survey cont inuing survey of food intake by individuals: men 19–50 years 1 day, 1985, Report No. 85-3, Nutrition and Monitoring Division, Human Nutrition Information Economic Research Service, U.S. Department of Agriculture, Hyattsville, MD
National Research Council (NRC) (1989) Recommended dietary allowances, 10th edn. National Academy Press, Washington
Doll R, Peto R (1981) The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States. J Natl Cancer Inst 66:1192–1308
Comstock GW, Helzlsouer KJ, Bush TL (1991) Prediagnostic serum levels of carotenoids and vitamin E as related to subsequent cancer in Washington County, Maryland. Am J Clin Nutr 53:260S–264S
Knekt P, Aromaa A, Maatala J, et al (1988) Serum vitamin E and risk of cancer among Finnish men during a 10-year follow-up. Am J EpidemioI 127:28–41
Hsing AW, Comstock GW, Abbey H, Polk BF (1990) Serologic precursors of cancer; retinol, carotenoids, and tocopherol and risk of prostate cancer. J Natl Cancer lnst 82:941–946
Eichholzer M, Stahelin HB, Gey FK, et al (1996) Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. lnt J Cancer 55:145–150
Hartman TJ, Albanes D, Pietinen P, et al (1998) The association between baseline vitamin E, selenium, and prostate cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cancer Epidemiol Biomarkers Prev 7:335–340
Rohan TE, Howe GR, Burch ID, et al (1995) Dietary factors and risk of prostate cancer: a case-control study in Ontario, Canada. Cancer Causes Control 6:145–154
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Klein, E.A. (2003). Clinical Models for Testing Chemopreventative Agents in Prostate Cancer and Overview of SELCT: The Selenium and Vitamin E Cancer Prevention Trial. In: Senn, HJ., Morant, R. (eds) Tumor Prevention and Genetics. Recent Results in Cancer Research, vol 163. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55647-0_19
Download citation
DOI: https://doi.org/10.1007/978-3-642-55647-0_19
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62892-4
Online ISBN: 978-3-642-55647-0
eBook Packages: Springer Book Archive